Yeah, hi. I hope we are able to hear it. Just one question on the US generics market. I m ean, you know from the data that we have; we see that there has been some significant erosion, price erosion in the month of April. How do you see that , I mean and what is the impact on our portfolio?
Yeah, okay, but I mean, have you seen some fall in pricing on the base business that's what I'm trying to underst and. I understand, I mean the new products and the other strategy that we use for getting the business, but has the base business?